52 Week Range
As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Cipla Sept-Quarter Consol Net Profit Rises
Cipla And Stempeutics Collaborate For Launch Of Stempeucel
India's Cipla June-Qtr Consol Net Profit Rises
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
Biotechnology & Drugs
Yusuf K. Hamied
Non-Executive Chairman of the Board
Global Chief Executive Officer, Managing Director, Executive Director
Executive Vice Chairman of the Board
M. K. Hamied
Non-Executive Vice Chairman of the Board
Global Chief Financial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
Indian shares rose on Monday, with the Nifty 50 extending gains into a fifth session, as a slew of upbeat pharma earnings reports and a rally in defence stocks helped investors look past concerns over surging coronavirus cases.
Indian shares rose and the Nifty 50 index gained for a fifth straight session on Monday, helped by gains in Cipla Ltd after the drugmaker posted a 21% jump in quarterly profit.
Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating.
Cipla Ltd <CIPL.NS> has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
* CIPLA LTD SAYS COMMERCIALLY LAUNCHES CIPREMI (REMDESIVIR) ON WEDNESDAY -STATEMENT
India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday.
Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.
India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.
* SIGNS DISTRIBUTION AGREEMENT WITH ROCHE PRODUCTS (INDIA) PVT. LTD
Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.
* CIPLA LTD -RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF MIGRANAL® (DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4MG/ML) Source text for Eikon: Further company coverage:
Indian shares slipped on Monday as investors were unimpressed by the government's economic relief measures and coronavirus cases continued to rise steadily, while a boost in Reliance Industries and Cipla limited losses.
* CIPLA FILES ANDA FOR GENERIC VERSION OF GSK'S ADVAIR DISKUS Source text for Eikon: Further company coverage:
* CIPLA LTD - APPROVED RAISING OF FUNDS OF UPTO 30 BILLION RUPEES Source text for Eikon: Further company coverage:
* MARCH QUARTER CONSOL NET PROFIT 2.46 BILLION RUPEES VERSUS PROFIT OF 3.67 BILLION RUPEES YEAR AGO
* CIPLA LIMITED ENTERS INTO A LICENSING AGREEMENT WITH GILEAD TO EXPAND ACCESS TO COVID-19 TREATMENT Source text for Eikon: Further company coverage:
* GILEAD SCIENCES - SIGNED NON-EXCLUSIVE VOLUNTARY LICENSING AGREEMENTS WITH 5 GENERIC PHARMACEUTICAL MANUFACTURERS BASED IN INDIA, PAKISTAN TO FURTHER EXPAND SUPPLY OF REMDESIVIR
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.